Mueller, Hermann L. and Gebhardt, Ursel and Schroeder, Sabine and Pohl, Fabian and Kortmann, Rolf-Dieter and Faldum, Andreas and Zwiener, Isabella and Warmuth-Metz, Monika and Pietsch, Torsten and Calaminus, Gabriele and Kolb, Reinhard and Wiegand, Christoph and Soerensen, Niels (2010) Analyses of Treatment Variables for Patients with Childhood Craniopharyngioma - Results of the Multicenter Prospective Trial KRANIOPHARYNGEOM 2000 after Three Years of Follow-Up. HORMONE RESEARCH IN PAEDIATRICS, 73 (3). pp. 175-180. ISSN 1663-2818,
Full text not available from this repository. (Request a copy)Abstract
Background: Controversies surround various treatment variables for patients with childhood craniopharyngioma such as growth hormone (GH) replacement, which some believe can exacerbate recurrence/progression. We prospectively assessed the risk of tumor recurrence/progression in survivors of childhood craniopharyngioma. Methods: Multivariable analyses of risk factors (age at diagnosis, degree of resection, irradiation, GH treatment and gender) and descriptive analyses of overall survival (OS) and event-free survival (EFS) rates were performed in 117 patients, recruited prospectively and evaluated after 3 years of follow-up in the German, Austrian and Swiss multicenter trial KRANIOPHARYNGEOM 2000. Results: We observed a 3-year OS of 0.97 and a 3-year EFS of 0.46, indicating high recurrence rates after complete resection (CR) (n = 47; 3-year-EFS: 0.64) and high progression rates after incomplete resection (IR) (n = 64; 3-year EFS: 0.31). The risk of an event decreased by 80% after CR compared to IR (hazard ratio = 0.20; p < 0.001). Irradiation had protective effects on EFS: irradiated patients had an 88% lower risk of recurrence/progression compared to patients without/before irradiation (hazard ratio = 0.12; p < 0.001). GH treatment had no impact on 3-year EFS rates. Conclusions: Tumor recurrences/progressions are frequent and occur early after initial treatment of childhood craniopharyngioma. A radical resection preserving the integrity of hypothalamic structures appears optimal at original diagnosis. Irradiation was efficient in preventing recurrences/progressions. GH treatment had no impact on the low 3-year EFS observed in our study. However, further conclusions on the influence of GH on recurrence rates have to be refined to long-term follow-up studies of patients with childhood craniopharyngioma. Copyright (C) 2010 S. Karger AG, Basel
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | GROWTH-HORMONE TREATMENT; BODY-MASS INDEX; QUALITY-OF-LIFE; BRAIN-TUMORS; SURVIVORS; THERAPY; RISK; REPLACEMENT; RECURRENCE; OUTCOMES; Childhood craniopharyngioma; Growth hormone; Recurrence; Survival; Hypothalamus |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Strahlentherapie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 17 Aug 2020 08:42 |
| Last Modified: | 17 Aug 2020 08:42 |
| URI: | https://pred.uni-regensburg.de/id/eprint/25470 |
Actions (login required)
 |
View Item |
